Sugi Predict

Sugi Predict / Compounds / SCHEMBL3961345

SCHEMBL3961345

SCHEMBL3961345

Nc1cc(F)c2[nH]ccc2c1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 1/20 0.42
▸ RIPK1 Q13546 1/20 0.42
▸ GPR84 Q9NQS5 1/20 0.42
▸ AHR P35869 3/20 0.36
▸ SLC6A2 P23975 9/20 0.35
▸ SLC6A4 P31645 9/20 0.35
▸ SLC6A3 Q01959 9/20 0.35
▸ CYP2D6 P10635 8/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ IKBKB O14920 3/20 0.33
▸ CHUK O15111 3/20 0.33
▸ ALOX5AP P20292 1/20 0.32
▸ FEN1 P39748 1/20 0.32
▸ PDPK1 O15530 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2537652 0.80 AHR (0.50) TNFRIPK1GPR84AHRSLC6A2
SCHEMBL16815127 0.78 IKBKB (0.35) TNFRIPK1GPR84AHRIKBKB
SCHEMBL16862049 0.77 GUSB (0.39) TNFRIPK1GPR84IKBKBCHUK
SCHEMBL14363462 0.77 GPR84 (0.34) TNFRIPK1GPR84AHRIKBKB
SCHEMBL794596 0.77 TNF (0.44) TNFRIPK1GPR84AHRSLC6A2
SCHEMBL120501 0.75 AHR (0.45) TNFRIPK1GPR84AHRSLC6A2
SCHEMBL2983533 0.75 ALDH1A1 (0.38) AHRIKBKBCHUKPDPK1
SCHEMBL14909105 0.75 TNF (0.57) TNFRIPK1GPR84AHRSLC6A2
SCHEMBL1394068 0.75 TNF (0.42) TNFRIPK1GPR84AHRSLC6A2
SCHEMBL30391792 0.75 AHR (0.45) TNFRIPK1GPR84AHRSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119790050-A Oxazole TRPML1 agonists and uses thereof 利布拉医疗公司 2025-04-08 — — CN disclosed
WO-2020142748-A1 METHODS AND MATERIALS FOR INCREASING TRANSCRIPTION FACTOR EB POLYPEPTIDE LEVELS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-07-09 — — WO disclosed
WO-2017153952-A1 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-09-14 — — WO disclosed
WO-2017098421-A1 BENZOTHIADIAZINE COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-06-15 — — WO disclosed
US-7544685-B2 2,3-dihydroindole compounds H. LUNDBECK A/S (DK) 2009-06-09 — — US disclosed
EP-1928860-A1 NOVEL 2,3-DIHYDROINDOLE COMPOUNDS H.Lundbeck A/S (DK) 2008-06-11 — — EP disclosed
WO-2007019867-A1 NOVEL 2,3-DIHYDROINDOLE COMPOUNDS H. LUNDBECK A/S (DK) 2007-02-22 — — WO disclosed
US-20070043058-A1 Novel 2,3-dihydroindole compounds H. LUNDBECK A/S (DK) 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043058-A1 Novel 2,3-dihydroindole compounds HTR2C, HTR2A, HTR5A TNF 3695/4885RIPK1 3941/4885GPR84 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.